Esperion Therapeutics develops and commercializes therapies for cardiometabolic and rare/orphan diseases, with a commercial focus on oral, once-daily, non-statin LDL-C treatments for patients at risk for cardiovascular disease. Company news commonly covers NEXLETOL bempedoic acid data, CLEAR Outcomes analyses, dyslipidemia guideline developments, financial results, business updates, and material agreements.
Esperion's news also reflects portfolio expansion through its completed acquisition of Corstasis Therapeutics and Enbumyst bumetanide nasal spray, an FDA-approved loop diuretic for edema associated with congestive heart failure and hepatic or renal disease in adults. Additional recurring topics include ACLY biology, product commercialization, pipeline work in Primary Sclerosing Cholangitis and renal diseases, and governance or capital-structure matters.
Esperion (NASDAQ: ESPR) announced that its CEO, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 4:40 p.m. ET. The event will be available via a live audio webcast on Esperion's investor relations website, with a replay accessible for 90 days afterward. Esperion is dedicated to developing oral medicines focused on lowering LDL-C to combat cardiovascular diseases, which affect millions in the U.S. Due to the high prevalence of elevated LDL-C levels, the company aims to offer effective solutions to improve patient outcomes.
Esperion (NASDAQ: ESPR) announced the launch of NEXLIZETTM (bempedoic acid and ezetimibe), the first approved non-statin LDL-C lowering combination medicine, now available in U.S. pharmacies. The drug achieves a mean LDL-C reduction of 38% when added to statins, with minimal paperwork for healthcare providers. NEXLIZET aims to set a new standard for affordability with broad payer coverage and a low co-pay for eligible patients. The launch has been accelerated by one month in response to healthcare provider requests, emphasizing the urgent need for additional cholesterol-lowering options.
Esperion (NASDAQ: ESPR) announced the grant of 88,902 restricted stock units (RSUs) to 194 new employees as part of its 2017 Inducement Equity Incentive Plan. The RSUs will vest over four years, with 25% after one year and the remaining 75% quarterly. This grant aims to attract talent as the company continues its mission of developing LDL-C lowering medicines to address cardiovascular disease. The press release contains forward-looking statements regarding clinical development and commercialization plans that carry inherent risks and uncertainties.
Esperion (NASDAQ: ESPR) announced that CEO Tim M. Mayleben will engage in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on May 12, 2020, at 9:00 a.m. ET. Interested parties can access a live audio webcast from the investor relations section of Esperion's website. The discussion will emphasize the company's efforts in cholesterol management, specifically targeting LDL-C levels. Esperion's mission is to develop oral medications that can significantly reduce LDL-C, combating the prevalence of cardiovascular diseases.
Esperion (NASDAQ:ESPR) announced the U.S. marketing approvals for NEXLETOL™ and NEXLIZET™ tablets, with NEXLETOL™ available from March 30 and NEXLIZET™ from June 4, 2020. The company reported first-ever product sales revenue of $1.8 million in Q1 2020, alongside a net loss of $78.2 million. Cash reserves totaled $158 million, bolstered by a $60 million collaboration payment. Esperion also anticipates a record revenue year driven by emerging sales and collaborations. A conference call is scheduled for May 6 to discuss the business outlook.